Ensemblins are a new class of synthetic macrocycles developed by Ensemble using its chemistry platforms, including DNA-Programmed Chemistry.
Macrocyclic rings are found in many natural product-based drugs and bestow favorable pharmaceutical properties and protein surface binding properties upon such drugs.
The alliance makes use of Ensemble’s proprietary drug discovery platforms and Ensemblin compound libraries to discover and advance drug candidates against up to eight pharmaceutical targets.
As per the extension of agreement, Ensemble will continue to pursue all collaboration targets.
Ensemble announced in April 2011, the achievement of the development of Ensemblins against one of the designated targets in the collaboration, resulting in transition of this drug target program to Bristol-Myers Squibb for further research and optimization and a milestone payment to Ensemble.